Xilio Therapeutics Income Statement (2024-2025) | XLO

Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 2.36M2.26M1.72M2.93M8.08M19.07M
Operating items
Research & Development 11.22M10.76M8.84M8.27M15.33M14.32M
Selling, General & Administrative 5.82M6.31M6.52M8.52M7.12M6.67M
Restructuring Costs 0.03M-0.04M
Operating Expenses 17.06M17.02M15.35M16.78M22.45M21.00M
Operating Income -14.70M-14.76M-13.63M-13.85M-14.37M-1.93M
EBIT -14.70M-14.76M-13.63M-13.85M-14.37M-1.93M
Non-operating items
Other Non Operating Income 0.78M0.74M0.54M0.59M-1.43M1.02M
Non Operating Income 0.78M0.74M0.54M0.59M-1.48M-14.36M
Net income details
EBT -14.70M-14.76M-13.63M-13.85M-14.37M-1.93M
Profit After Tax -13.93M-14.02M-13.09M-13.30M-14.37M-1.93M
Income from Continuing Operations -14.70M-14.76M-13.63M-13.85M-14.37M-1.93M
Consolidated Net Income -14.70M-14.76M-13.63M-13.85M-14.37M-1.93M
Income towards Parent Company -14.70M-14.76M-13.63M-13.85M-14.37M-1.93M
Net Income towards Common Stockholders -14.70M-14.76M-13.63M-13.85M-14.37M-1.93M
Additional items
EPS (Basic) -0.24-0.22-0.25-0.18-0.16-0.11
EPS (Weighted Average and Diluted) -0.24-0.22-0.25-0.18-0.16-0.11
Shares Outstanding (Weighted Average) 27.91M57.76M63.47M53.51M74.70M96.45M144.11M
Shares Outstanding (Diluted Average) 27.91M57.76M63.47M53.51M74.70M96.45M144.11M
EBITDA -13.93M-14.02M-13.09M-13.27M-15.84M-16.29M